Mesaconic acid delivery via biomaterials and engineered probiotics to the gut reduces inflammation in Crohn's Diseases mouse models
Qian, H.; Singh, D.; Chen, Z.; Zhao, W.; Zhang, B.; Knodaei, T.; Thumsi, A.; Pathak, S.; Suresh, A.; Menghini, P.; Schiek, J.; Rabara, V.; Salvo, C. D.; Baskaran, H.; Aso, Y.; Jaggarapu, M. M. C. S.; Basson, A. R.; Acharya, A. P.
Show abstract
Mesaconate (MES, an immunosuppressive metabolite) but not itaconate is upregulated in stool of Crohns Disease (CD) patients, albeit below therapeutic levels.. However, colonic MES level is difficult to maintain because of its high absorption rate, limiting its therapeutic potential for CD. Herein, we developed two strategies that elevate MES level and suppress inflammation: EcN-CAD, an engineered probiotic Escherichia coli Nissle 1917 (EcN) that overexpresses cis-aconitate decarboxylase (CAD, produces itaconic acid that is converted to MES); and MES+Zn, a Zinc-MES ionically crosslinked formulation. Mechanistically, MES modulates T cell function by downregulating glycolytic and mitochondrial activity and decrease ROR{gamma}t expression. In preclinical SAMP1/YitFC dexamethasone-withdrawal model and TNFDARE model, MES+Zn decreased gut permeability significantly compared to controls and reduced myeloperoxidase (MPO, an inflammatory marker) 1000-fold compared to controls. EcN-CAD probiotics decreased ROR{gamma}t expression in CD4+ and CD8+ T cells, gut permeability and inflammation in preventive SAMP1/YitFC model, and SAMP1/YitFC dexamethasone-withdrawal model. Overall, MES rewires T cell responses and technologies that enhance MES levels can be effective in gut-related inflammatory diseases.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effects of a spore-forming probiotic blend on bowel habits and physical well-being in adults with functional constipation: a randomized, double-blind, placebo-controlled trial 92%
- An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease 92%
- Impact of time and temperature on gut microbiota and SCFA composition in stool samples 91%
Similar papers in this journal
- Secondary bile acid lithocholic acid ameliorates colitis-like inflammation in a human intestine-on-chip system 93%
- Gut bacterial metabolite Urolithin A (UA) mitigates Ca2+ 1 entry inT cells by regulating miR-10a-5p 92%
- Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA(R)) Platform Elicits Enhanced Humoral and Cellular Immune Responses 90%
Similar papers in this journal
- Appearance of green tea compounds in plasma following acute green tea consumption is modulated by the gut microbiome in mice 91%
- Activated carbon ameliorates type 2 diabetes via metabolic remodeling of the gut microbiota 90%
- Evaluation of a throat spray with lactobacilli in COVID-19 outpatients in a randomized, double-blind, placebo-controlled trial for symptom and viral load reduction 89%
Similar papers in this journal
- Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome 94%
- Rapamycin Immunomodulation Utilizes Time-Dependent Alterations of Lymph Node Architecture, Leukocyte Trafficking, and Gut Microbiome 89%
- Aberrant miR-29 is a predictive feature of severe phenotypes in pediatric Crohn's disease 88%
Similar papers in this journal
- Identification and Validation of Small Molecules with Mucin-Selective Regiospecific Binding in the Gastrointestinal Tract 90%
- Antigen-Specific Immune Decoys Intercept and Exhaust Autoimmunity to Prevent Disease 89%
- Thiol-ene cross-linked alginate hydrogel encapsulation modulates the extracellular matrix of kidney organoids by reducing abnormal type 1a1 collagen deposition 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.